Steatosis is a build-up of fat inside the liver cells. It is not cancer, and on its own, it is the mildest stage of fatty liver disease. Steatosis is very common, and many people with it have no symptoms. It matters because, in some people, the fat triggers inflammation and scarring that can damage the liver over many years.
This article explains what liver steatosis means, what causes it, and how pathologists grade it. It also describes the other findings in a liver biopsy report. It also explains the newer names, such as MASLD, that may appear on your report.
The liver is made mostly of cells called hepatocytes. These cells store, process, and release fat as part of their normal work. Steatosis means hepatocytes store more fat than they can use or release. Under the microscope, the stored fat looks like round, empty bubbles inside the cells.
A small amount of fat in the liver is normal. Pathologists call it steatosis when more than 5% of hepatocytes contain fat. The fat usually builds up first around the small veins in the center of each liver unit, an area pathologists call zone 3.
Doctors now use the term steatotic liver disease for any liver condition in which steatosis is the main finding. Steatosis is the finding under the microscope, and the full diagnosis also names its cause.
Steatosis develops when more fat reaches the liver than it can burn or export. This can happen because the body has too much fat and sugar in the blood, because a substance damages the liver’s ability to process fat, or both. Common causes include:
The names used for fatty liver disease changed in 2023. That year, international liver societies agreed on a new set of names through a formal consensus process. The older names were based on what the disease was not, and many patients found the words “nonalcoholic” and “fatty” stigmatizing. You may see either the old or the new names on your reports, depending on when and where they were written.
The five cardiometabolic risk factors used to diagnose MASLD in adults are:
A pathologist can see steatosis under the microscope but usually cannot tell the cause from the biopsy alone. The final name is chosen by your doctor, who combines the biopsy with your health history, blood tests, and alcohol use.
Liver steatosis is one of the most common conditions in the world. An analysis for the Global Burden of Disease study estimated that about 1.3 billion people, or 16% of the world’s population, had MASLD in 2023. In the United States, it affects about 30% of adults and up to 65% of people with type 2 diabetes. It is becoming more common in children and young adults as rates of obesity rise.
Most people with steatosis of the liver have no symptoms. Steatosis is often found by chance on an ultrasound, CT scan, or MRI done for another reason. It may also be suspected because of mildly raised liver enzymes on a liver blood test panel. Some people feel tired or have a dull ache in the upper right side of the abdomen, but these symptoms are not specific to steatosis.
Steatosis of the liver is usually found first on imaging. Most people never need a biopsy, because imaging and blood tests can measure liver fat and estimate scarring. A liver biopsy is done when the cause is unclear, when another liver disease is suspected, or when doctors need to know how much inflammation and scarring is present. Steatosis is also often noticed in liver tissue removed for another reason, such as a tumor or a liver donation.
A needle biopsy removes a thin core of liver tissue, usually through the skin under a local anesthetic. The pathologist examines the tissue under the microscope after staining it with hematoxylin and eosin (H&E). Fat dissolves during tissue processing, so fat droplets look like clear, empty bubbles. The pathologist estimates what percentage of the liver contains fat and looks for signs of injury and scarring.
Most liver biopsies also receive special stains. A trichrome stain colors scar tissue blue so the pathologist can measure scarring. A reticulin stain shows the framework of the liver, and an iron stain shows whether extra iron is stored in the liver.
Steatosis of the liver is graded by the percentage of liver tissue that contains fat. Most pathologists use the system published by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) in 2005. Your report may give the grade as a word, a number, or a percentage:
The grade describes only how much fat is present. It does not measure inflammation or scarring, which are reported separately and matter more for the liver’s long-term health. A person with grade 3 steatosis and no scarring may be at lower risk than a person with grade 1 steatosis and significant scarring. People with more fat are, however, more likely to also have steatohepatitis.
Pathologists describe steatosis by the size of the fat droplets because droplet size points to different causes.
Widespread microvesicular steatosis is different. It suggests that the liver cells cannot burn fat for energy. It is rare and can be serious. Causes include some medications, such as valproic acid and tetracycline, a pregnancy condition called acute fatty liver of pregnancy, and Reye syndrome in children.
A liver biopsy report for steatosis usually describes several other features. These features help your doctor decide whether the liver has simple steatosis or a more active disease.
Steatosis and steatohepatitis are two stages of the same disease. When the biopsy shows fat with little or no liver cell injury, the report may call it steatosis, simple steatosis, or steatotic liver disease without steatohepatitis. When the biopsy shows fat together with inflammation and ballooned liver cells, the diagnosis is steatohepatitis. Steatohepatitis is more likely to lead to scarring.
Some reports also give a NAFLD activity score (NAS), which adds the scores for steatosis, inflammation, and ballooning. Our article on steatohepatitis explains this score and the fibrosis stages in more detail.
For most people, steatosis of the liver without scarring stays stable for many years. It can also improve when you treat the cause. Still, steatosis is not completely harmless. Roughly 20% to 30% of people with metabolic steatosis go on to develop steatohepatitis. Large studies have also found a somewhat higher risk of death in people with simple steatosis than in the general population. Much of that extra risk comes from heart disease, not the liver.
The fibrosis stage is the strongest predictor of future liver problems. In a Swedish study that followed people for up to 33 years, those with stage 3 or 4 fibrosis had about three times the risk of death. People with active steatohepatitis but little scarring did not have a clearly higher risk. Advanced scarring raises the risk of cirrhosis, liver failure, and liver cancer.
Once steatosis of the liver has been confirmed by pathology, the next steps depend on its cause and on the amount of inflammation and scarring in your report. Your doctor will usually look for and treat the underlying cause.
No medication is approved to treat steatosis on its own. Two medications are approved for people who have steatohepatitis with moderate to advanced scarring (fibrosis stage 2 or 3) but not cirrhosis. The US Food and Drug Administration (FDA) granted accelerated approval to resmetirom in March 2024. Semaglutide received FDA accelerated approval in August 2025 and conditional authorization from Health Canada in late 2025. Because these approvals depend on biopsy findings, the fibrosis stage on your report helps determine whether this treatment is an option.
People with steatosis are usually followed with blood tests and non-invasive scans that measure liver stiffness, rather than repeat biopsies. A hepatologist, a doctor who specializes in the liver, may be involved if scarring is present.